S(+)-ketamine suppresses desensitization of γ-aminobutyric acid type B receptor-mediated signaling by inhibition of the interaction of γ-aminobutyric acid type B receptors with G protein-coupled receptor kinase 4 or 5

Anesthesiology

Volumn 114, Issue 2, 2011, Pages 401-411

  Ando, Yuko ^a   Hojo, Minoru ^a   Kanaide, Masato ^a   Takada, Masafumi ^b   Sudo, Yuka ^a   Shiraishi, Seiji ^b   Sumikawa, Koji ^a   Uezono, Yasuhito ^b  

^a NAGASAKI UNIVERSITY GRADUATE SCHOOL OF BIOMEDICAL SCIENCES   (Japan)

^b NATIONAL CANCER CENTER RESEARCH INSTITUTE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOBUTYRIC ACID B RECEPTOR; BACLOFEN; FLUORESCENT DYE; G PROTEIN COUPLED INWARDLY RECTIFYING POTASSIUM CHANNEL; G PROTEIN COUPLED RECEPTOR KINASE 4; G PROTEIN COUPLED RECEPTOR KINASE 5; KETAMINE;

ANIMAL CELL; ARTICLE; CELL MEMBRANE; COMPLEX FORMATION; CONFOCAL MICROSCOPY; CONTROLLED STUDY; ELECTROPHYSIOLOGY; FLUORESCENCE RESONANCE ENERGY TRANSFER; HAMSTER; IMMUNOPRECIPITATION; KIDNEY CELL; MORPHINE TOLERANCE; NONHUMAN; OOCYTE; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; RECEPTOR DOWN REGULATION; WESTERN BLOTTING; XENOPUS;

EID: 79251642967     PISSN: 00033022     EISSN: 15281175     Source Type: Journal    
DOI: 10.1097/ALN.0b013e318204e003     Document Type: Article

References (43)

1. Slonimski M, Abram SE, Zuniga RE: Intrathecal baclofen in pain management. Reg Anesth Pain Med 2004; 29:269-76
2. Zuniga RE, Schlicht CR, Abram SE: Intrathecal baclofen is analgesic in patients with chronic pain. ANESTHESIOLOGY 2000; 92:876-80
3. Taira T, Hori T: Intrathecal baclofen in the treatment of post-stroke central pain, dystonia, and persistent vegetative state. Acta Neurochir Suppl 2007; 97:227-9
4. Van Hilton BJ, Van de Beek WJT, Hoff JI, Voormolen JHC, Delhaas EM: Intrathecal baclofen for the treatment of dystonia in patients with reflex sympathetic dystrophy. N Engl J Med 2000; 343:625-30
5. Zuniga RE, Perera S, Abram SE: Intrathecal baclofen: A useful agent in the treatment of well-established complex regional pain syndrome. Reg Anesth Pain Med 2002; 27:90-3
6. Nielsen JF, Hansen HJ, Sunde N, Christensen JJ: Evidence of tolerance to baclofen in treatment of severe spasticity with intrathecal baclofen. Clin Neurol Neurosurg 2002; 104:142-5
7. Kanaide M, Uezono Y, Matsumoto M, Hojo M, Ando Y, Sudo Y, Sumikawa K, Taniyama K: Desensitization of GABAB receptor signaling by formation of protein complexes of GABAB2 subunit with GRK4 or GRK5. J Cell Physiol 2007; 210:237-45
8. Perroy J, Adam L, Qanbar R, Chenier S, Bouvier M: Phosphorylation- independent desensitization of GABAB receptor by GRK4. EMBO J 2003; 22:3816-24
9. Pitcher JA, Freedman NJ, Lefkowitz RJ: G protein-coupled receptor kinases. Annu Rev Biochem 1998; 67:653-92
10. Wallace M, Yaksh TL: Long-term spinal analgesic delivery: A review of the preclinical and clinical literature. Reg Anesth Pain Med 2000; 25:117-57
11. Kedlaya D, Reynolds L, Waldman S: Epidural and intrathecal analgesia for cancer pain. Best Pract Res Clin Anaesthesiol 2002; 16:651-65
12. Kosson D, Klinowiecka A, Kosson P, Bonney I, Carr D, Mayzner-Zawadzka E, Lipkowski A: Intrathecal antinociceptive interaction between the NMDA antagonist ketamine and the opioids, morphine and biphalin. Eur J Pain 2008; 12: 611-6
13. Miyamoto H, Saito Y, Kirihara Y, Hara K, Sakura S, Kosaka Y: Spinal coadministration of ketamine reduces the development of tolerance to visceral as well as somatic antinociception during spinal morphine infusion. Anesth Analg 2000; 90:136-41
14. Shimoyama N, Shimoyama M, Inturrisi CE, Elliott K: Ketamine attenuates and reverses morphine tolerance in rodents. ANESTHESIOLOGY 1996; 85:1357-66
15. Zhang J, Ferguson SSG, Barak LS, Bodduluri SR, Laporte SA, Law PY, Caron MG: Role for G protein-coupled receptor kinase in agonist-specific regulation of-opioid receptor responsiveness. Proc Natl Acad Sci USA 1998; 95:7157-62
16. Terman GW, Jin W, Cheong YP, Lowe J, Caron MG, Lefkowits RJ, Chavkin C: G-protein receptor kinase 3 (GRK3) influences opioid analgesic tolerance but not opioid withdrawal. Br J Pharmacol 2004; 141:55-64
17. Kovoor A, Nappey V, Kieffer BL, Chavkin C:- And- opioid receptors are differentially desensitized by the coexpression of-adrenergic receptor kinase 2 and-arrestin 2 in Xenopus oocyte. J Biol Chem 1997; 272:27605-11
18. Craven R: Ketamine. Anesthesia 2007; 62:48-53
19. Ivanina T, Varon D, Peleg S, Rishal I, Porozov Y, Dessauer CW, Keren-Raifman T, Dascal N: G-i1 and G-i3 differentially interact with, and regulate, the G protein-activated K- channel. J Biol Chem 2004; 279:17260-8
20. Uezono Y, Kanaide M, Kaibara M, Barzilai R, Dascal N, Sumikawa K, Taniyama K: Coupling of GABAB receptor GABAB2 subunit to G proteins: Evidence from Xenopus oocyte and baby hamster kidney cell expression system. Am J Physiol Cell Physiol 2006; 290:C200 -7
21. Uezono Y, Bradley J, Min C, McCarty NA, Quick M, Riordan JR, Chavkin C, Zinn K, Lester HA, Davidson N: Receptors that couple to 2 classes of G proteins increase cAMP and activate CFTR expressed in Xenopus oocytes. Receptor Channels 1993; 1:233-41
22. Uezono Y, Akihara M, Kaibara M, Kawano C, Shibuya I, Ueda Y, Yanagihara N, Toyohira Y, Yamashita H, Taniyama K, Izumi F: Activation of inwardly rectifying K- channels by GABA-B receptors expressed in Xenopus oocytes. Neuroreport 1998; 9:583-7
23. Villemure JF, Adam L, Bevan NJ, Gearing K, Chenier S, Bouvier M: Subcellular distribution of GABAB receptor homoand hetero-dimers. Biochem J 2005; 388:47-55
24. Miyawaki A, Tsien RY: Monitoring protein conformations and interactions by fluorescence resonance energy transfer between mutants of green fluorescent protein. Methods Enzymol 2000; 327:472-500
25. Riven I, Kalmanzon E, Segev L, Reuveny E: Conformational rearrangements associated with the gating of the G proteincoupled potassium channel revealed by FRET microscopy. Neuron 2003; 38:225-35
26. Penn RD, Kroin JS: Intrathecal baclofen alleviates spinal cord spasticity. Lancet 1984; 12:1078
27. Hefferan MP, Fuchigami T, Marsala M: Development of baclofen tolerance in a rat model of chronic spasticity and rigidity. Neurosci Lett 2006; 403:195-200
28. Vidal J, Gregori P, Guevara D, Portell E, Valles M: Efficacy of intrathecal morphine in the treatment of baclofen tolerance in a patient on intrathecal baclofen therapy (ITB). Spinal Cord 2004; 42:50-1
29. Soni BM, Mani RM, Oo T, Vaidyanathan S: Treatment of spasticity in a spinal cord-injured patient with intrathecal morphine due to intrathecal baclofen tolerance: A case report and review of literature. Spinal Cord 2003; 41:586-9
30. Kroin JS, Bianchi GD, Penn RD: Intrathecal baclofen downregulates GABAB receptors in the rat substantia gelatinosa. J Neurosurg 1993; 79:544-9
31. Bell RF: Ketamine for chronic non-cancer pain. Pain 2009; 141:210-4
32. Okon T: Ketamine: An introduction for the pain and palliative medicine physician. Pain Physician 2007; 10:493-500
33. Durieux ME: Inhibition by ketamine of muscarinic acetylcholine receptor function. Anesth Analg 1995; 81:57-62
34. Sarton E, Teppema LJ, Olivier C, Nieuwenhuijs D, Matthes HWD, Kieffer BL, Dahan A: The involvement of the-opioid receptor in ketamine-induced respiratory depression and antinociception. Anesth Analg 2001; 93:1495-500
35. Okamoto T, Minami K, Uezono Y, Ogata J, Shiraishi M, Shigematsu A, Ueta Y: The inhibitory effects of ketamine and pentobarbital on substance P receptors expressed in Xenopus oocytes. Anesth Analg 2003; 97:104-10
36. Schnoebel R, Wolff M, Peters SC, Brau ME, Scholz A, Hempelmann G, Olschewski H, Olshewski A: Ketamine impairs excitability in superficial dorsal horn neurons by blocking sodium and voltage-gated potassium currents. Br J Pharmacol 2005; 146:826-33
37. Errando CL, Sifre C, Moliner S, Valia JC, Gimeno O, Minguez A, Boils P: Subarachnoid ketamine in swine-pathological findings after repeated doses: Acute toxicity study. Reg Anesth Pain Med 1999; 24:146-52
38. Malinovsky JM, Lepage JY, Cozian A, Mussini JM, Pinaudt M, Souron R: Is ketamine or its preservative responsible for neurotoxicity in the rabbit? ANESTHESIOLOGY 1993; 78:109-15
39. Yaksh TL, Tozier N, Horais KA, Malkmus S, Rathbun M, LaFranco L, Eisenach J: Toxicology profile of N-methyl-Daspartate antagonists delivered by intrathecal infusion in the canine model. ANESTHESIOLOGY 2008; 108:938-49
40. Vranken JH, Troost D, de Hssn P, Pennings FA, van der Vegt MH, Dijlgraaf MGW, Hollmann MW: Severe toxic damage to the rabbit spinal cord after intrathecal administration of preservative-free S(-)-ketamine. ANESTHESIOLOGY 2006; 105: 813-8
41. Karpinski N, Dunn J, Hansen L, Masliah E: Subpial vacuolar myelopathy after intrathecal ketamine: Report of a case. Pain 1997; 73:103-5
42. Vranken JH, Troost D, Wegener JT, Kruis MR, van der Vegt MH: Neuropathological findings after continuous intrathecal administration of S(-)-ketamine for the management of neuropathis cancer pain. Pain 2005; 117:231-5
43. Farber NB, Kim SH, Dikranian K, Jiang XP, Heinkel C: Receptor mechanisms and circuitry underlying NMDA antagonist neurotoxicity. Mol Psychiatry 2002; 7:32-43